Trek for 43
Impact Report
Make an impact in your own way with our DIY fundraising tools.
Find clinical trails that may benefit your child.
previous arrow
next arrow
Slider

We’re driving critical collaborations to accelerate the pace of pediatric drug development

With the unmatched expert leadership of our Scientific and Industry Councils, we identify and fund only the most innovative research with the potential to move quickly into the clinic and marketplace, reaching children now – not 10-20 years from now.

AN URGENT UNMET NEED: Cancer is the #1 Disease Killer in Children

Fact:

Fact:

Fact:

Leaders from across the pediatric cancer ecosystem explain the urgent, critical need for new childhood cancer treatments, and how CureSearch is changing the odds for the 43 children diagnosed each day.

Our Impact on Children

drugs

30 New Drugs In
Pre-Clinical Testing

Using models developed from the tumors of pediatric cancer patients or made through genetic manipulation of cells, CureSearch investigators are testing novel treatment strategies in their labs. These innovative therapeutics have been designed to address tumors of high unmet need, with low survival or insufficient safe treatment options. If these potential therapies successfully reduce tumor burden with minimal side-effects in the tumor models systems, these treatment options will quickly move out of the lab and into clinical trials.

AML

1 Novel Cell Therapy for AML

Pediatric AML patients undergo aggressive chemotherapy followed by stem cell transplant, a standard of care that can cause a highly toxic side-effect, the leading cause of patient mortality. CureSearch Acceleration Initiative investigator Dr. Maria-Grazia Roncarolo has developed a first-of-its-kind cell therapy that will reduce the toxicity associated with standard AML treatment while retaining the anti-leukemia benefits.

giloma

1 Clinical Trial for High Grade Glioma

CureSearch Catapult Award recipient Dr. Ranjit Bindra has initiated a phase 1 clinical trial to test a new, less toxic treatment for pediatric glioma, an aggressive type of brain cancer with a 5 year survival rate of less than 25%. Dr. Bindra’s cutting-edge study could significantly improve long-term survival rates and reduce toxicity in pediatric glioma patients, and lead to a potential shift in treatment standards.

300+

300+ Potential New Drug Targets

CureSearch investigators have assessed biopsies, cell lines, and animal models derived from patients with pediatric cancers including ALL, AML, medulloblastoma, ependymoma, choroid plexus carcinoma, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and Wilms tumor. This work has led to the identification of over 300 new potential drug targets that are now moving to preclinical evaluation

W=Ewing sarcoma

1 Novel Drug for Ewing Sarcoma

Dr. Mary Beckerle, an Acceleration Initiative awardee, collaborated with a team of investigators at the Huntsman Cancer Institute to develop and test a novel agent for the treatment of Ewing sarcoma. Pre-clinical studies performed using this drug formed the foundation to support a compassionate use study in 2017 followed by a phase 1 clinical trial in patients with relapsed or refractory Ewing sarcoma that is currently recruiting patients.

recurrent

1 New Treatment for Recurrent, Refractory Medulloblastoma

With his Acceleration Initiative Award, Dr. Richard Gilbertson’s goal was to utilize his lab’s innovative preclinical trials platform to provide colleagues with all of the information necessary to initiate a clinical trial. He met his goal when he provided the data necessary to initiate a phase 1 clinical trial at St. Jude in February 2018. This trial, which is currently recruiting patients, will assess combination therapy in recurrent, refractory Group 3 medulloblastoma patients.

Together, We Are Making an Impact

It is our goal to protect the future of children diagnosed with cancer by delivering better, less-toxic treatments. This can’t happen without your help. We thank you for your support in the fight against children’s cancer.

Read our latest Impact Report

Spring 2019 Impact Report

Read about how together we are making great strides through our research strategy in our latest Impact Report.

Get Involved and Help End Children’s Cancer!

hike

Ultimate Hike

Tell children’s cancer to “take a hike” and join us for a life changing, lifesaving adventure on one of the country’s most iconic trails.

walk

CureSearch Walk

Form a team in your community, raise critical funds, and walk in honor of the 43 children diagnosed each day.

gold-c

CureSearch Gold

Create your own fundraising event to help end childhood cancer; from golf tournaments to backyard BBQ’s, the possibilities are endless!

challenge-c

CureSearch Challenge

Go the extra mile for your favorite race or join our team for a
featured event.

fundraise

Volunteer Opportunities

Lend your time, skills, expertise and passion in support of our shared mission to end children’s cancer.

corporate

Corporate Partnerships

Engage your employees, customers and communities by partnering with us to help end children’s cancer.

Unmatched Expert Leadership

Our Scientific and Industry Advisory Councils are comprised of experts at the top of their fields, and validation of a research project by our Scientific Review Committee speaks volumes in the global pediatric cancer arena.

Led by Richard J. O’Reilly, MD
The Scientific Advisory Council includes leading pediatric oncologists who set the academic priorities for CureSearch research initiatives and evaluate projects on scientific merit.
Led by Samuel Blackman, MD, PhD
The Industry Advisory Council includes leaders from the largest global oncology and biotechnology companies who champion pediatric cancer programs and review potential research projects for clinical and regulatory feasibility.
Led by Stephan Sallan, MD
Our Scientific Review Committee provides rigourous peer review of research proposals, evaluating: scientific merits, innovation, unmet need and clinical impacts.

Our Corporate Partners

ironhill

"We’re proud to be a long-time partner of CureSearch with 10+ years of support for children’s cancer research. This relationship demonstrates to both the employees and customers of Iron Hill Brewery & Restaurant that we care deeply about the wider community that we serve. We know CureSearch is hard at work finding new treatment options for kids and together we are helping to put an end to childhood cancer."

Kevin Finn

Founder and President, Iron Hill Brewery & Restaurant
Kiewit

"Our annual Jakefest events honor the memory of my son, Jake, who passed away after a heroic fight with rhabdomyosarcoma. Kiewit has partnered with CureSearch because they're uniquely positioned to accelerate the pace of finding new drugs for kids. Through the generosity of Kiewit's employees, their spouses, friends, relatives, and our gracious business partners, over $3,000,000 has been raised for CureSearch. We could hardly have imagined twelve years ago the outpouring of goodwill this event has brought."

Harry Koenigs, Jake's Dad

Area Manager, Kiewit

Pin It on Pinterest

Scroll to Top